# Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct06631092/  
OnCo record `nct06631092` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Oral DNA Vaccine in triple-negative breast cancer, run by NEC Bio B.V, now recruiting.

## Summary

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer is a phase 1/2 interventional study registered as NCT06631092 by NEC Bio B.V, with 28 participants planned, started 2024-11-20 and due to reach its primary completion in 2027-12-31. Interventions recorded: Oral DNA Vaccine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06631092
- Phase: 1/2
- Setting: An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 as add-on to First-line Neoadjuvant Anti-PD-1 Monoclonal Antibody Therapy in Patients With Triple-negative Breast Cancer
- Sponsor: NEC Bio B.V
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT06631092: https://clinicaltrials.gov/study/NCT06631092

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)

---
JSON: https://onco.cc/api/v1/entities/nct06631092.json